Medicinal Chemistry News and Research

RSS

Heptares exercises exclusive option to license new A2A antagonist for CNS disorders

Heptares Therapeutics, the leading GPCR drug discovery company, announces that an operating company of Shire PLC, the global specialty biopharmaceutical company, has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development.

20 Mar 2012

ITQB, REQUIMTE convert solid antibiotic ampicilin into an ionic liquid form

In a daring move into the biomedical arena, ITQB chemists from the Molecular Thermodynamics Lab and collaborators from REQUIMTE have managed to convert the solid antibiotic ampicilin into an ionic liquid form, a method that may be extended to other pharmaceutical compounds with benefits for their administration. The work is now published in Medicinal Chemistry Communications.

12 Mar 2012

New hybrid aspirin shrinks tumors, curbs cancer cell growth

The humble aspirin may soon have a new role. Scientists from The City College of New York have developed a new aspirin compound that has great promise to be, not only an extremely potent cancer-fighter, but even safer than the classic medicine cabinet staple.

9 Mar 2012

Scripps scientists to develop new generation of broad spectrum anti-cancer therapeutics

A pair of Scripps Research Institute scientists, one a cancer biologist and the other a chemist, has been awarded $3.85 million from the National Institutes of Health (NIH) to develop a new generation of broad spectrum anti-cancer therapeutics, including breast cancer and lymphoma.

6 Mar 2012

Scripps Florida study to focus on four new classes of pain-relieving compounds

Scripps Florida scientists have been awarded $3.1 million by the National Institute on Drug Abuse, part of the National Institutes of Health, to study and develop several new compounds that could prove to be effective in controlling pain without the unwanted side effects common with opiate drugs, such as morphine, Oxycontin, and Vicoden.

1 Mar 2012

New NOSH-aspirin appears more effective against cancer

Scientists have combined two new "designer" forms of aspirin into a hybrid substance that appears more effective than either of its forebears in controlling the growth of several forms of cancer in laboratory tests. Their report on the new NOSH-aspirin, so named because it releases nitric oxide (NO) and hydrogen sulfide (H2S), appears in the journal ACS Medicinal Chemistry Letters.

29 Feb 2012

CNRS/Inserm researchers discover new family of anti-cancer compounds

A French-Italian team headed by researchers from CNRS and Inserm has discovered a new family of compounds that could make it possible to treat numerous cancers, particularly brain tumors and skin cancers.

28 Feb 2012

Study reveals how mutation shuts down DJ-1 protein's neuroprotective abilities

Purdue University researchers revealed how a mutation in a protein shuts down a protective function needed to prevent the death of neurons in Parkinson's disease, possibly opening the door to new drug strategies to treat the disorder.

22 Feb 2012

Compound makes imipenem 16 times more effective against antibiotic-resistant K. pneumoniae

North Carolina State University chemists have created a compound that makes existing antibiotics 16 times more effective against recently discovered antibiotic-resistant "superbugs."

14 Feb 2012

TGen, UA receive NFCR grant to study targeted pancreatic cancer therapies

The Translational Genomics Research Institute (TGen) and the University of Arizona (UA) have received a three-year, $600,000 grant to study targeted cancer therapies from the National Foundation for Cancer Research.

1 Feb 2012

LEITAT, JPT and IUCT partner to develop enhanced anticancer therapy

JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG, IUCT and LEITAT announced today their collaboration on the joint development of an enhanced anticancer therapy based on the biofocused targeting of nucleoside analogs linked to small cyclic peptidomimetics.

18 Jan 2012

UI chemists debunk misconception about amphotericin

With one simple experiment, University of Illinois chemists have debunked a widely held misconception about an often-prescribed drug.

17 Jan 2012

Researchers discover a way to sensitize glioblastoma to chemotherapy

Brain cancer cells are particularly resistant to chemotherapy - toxins enter the cells, but before the toxins can kill, cancer cells quickly pump them back outside. In fact, brain cancer cells are even better than healthy cells at cleaning themselves. This means that when hit with chemotherapy, healthy cells tend to die before brain cancer cells. Especially in the brain, killing healthy cells is bad.

13 Jan 2012

New imaging agent shows promise in detecting signs of AD

Scientists are reporting development and initial laboratory tests of an imaging agent that shows promise for detecting the tell-tale signs of Alzheimer's disease (AD) in the brain - signs that now can't confirm a diagnosis until after patients have died.

12 Jan 2012

Scripps professor receives pair of notable grants to study kinesin

Sathyanaryanan Puthanveettil, an assistant professor on the Florida campus of The Scripps Research Institute, has been awarded a pair of notable grants to study a critical component of long-term memory formation.

6 Jan 2012

Ipsen, Oncodesign partner to discover and develop LRRK2 kinase inhibitors against PD

Oncodesign, a Drug Discovery company and Oncology pharmacology service provider, and Ipsen, a global specialty-driven pharmaceutical company, announced today that the two companies have entered into a research collaboration to discover and develop innovative LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson's Disease and for potential additional uses in other therapeutic areas.

5 Jan 2012

New compound circumvents drug-efflux pumps associated with Gram-positive bacteria

It's no wonder that medicine's effort to combat bacterial infections is often described as an arms race. When new drugs are developed to combat infections, the bacterial target invariably comes up with a deterrent.

29 Nov 2011

Oral delivery of PYY hormone can help obese people lose weight

Most people understand that serious weight loss requires changing attitudes toward what they eat and how often they exercise. But, what if the process could be aided by simply chewing a stick of gum after meals? That's the question a team of scientists, led by Syracuse University chemist Robert Doyle, is trying to answer. In a groundbreaking new study, Doyle's team demonstrated, for the first time, that a critical hormone that helps people feel "full" after eating can be delivered into the bloodstream orally.

22 Nov 2011

AMRI reports $50.2 million total revenue for third quarter 2011

...

9 Nov 2011

New technologies could aid in malignant melanoma diagnosis and therapy

Because the incidence of malignant melanoma is rising faster than any other cancer in the U.S., researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues at Tampa-based Intezyne Technologies, Inc., Western Carolina University and the University of Arizona are working overtime to develop new technologies to aid in both malignant melanoma diagnosis and therapy.

4 Nov 2011